HomeCompareGGDVF vs ABBV

GGDVF vs ABBV: Dividend Comparison 2026

GGDVF yields 4.94% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $81.1K in total portfolio value
10 years
GGDVF
GGDVF
● Live price
4.94%
Share price
$0.88
Annual div
$0.04
5Y div CAGR
-33.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.3K
Annual income
$8.64
Full GGDVF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GGDVF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGGDVFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GGDVF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GGDVF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GGDVF
Annual income on $10K today (after 15% tax)
$420.23/yr
After 10yr DRIP, annual income (after tax)
$7.34/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,048.66/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GGDVF + ABBV for your $10,000?

GGDVF: 50%ABBV: 50%
100% ABBV50/50100% GGDVF
Portfolio after 10yr
$61.8K
Annual income
$12,390.20/yr
Blended yield
20.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GGDVF
No analyst data
Altman Z
2.0
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GGDVF buys
0
ABBV buys
0
No recent congressional trades found for GGDVF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGGDVFABBV
Forward yield4.94%3.06%
Annual dividend / share$0.04$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-33.8%40.6%
Portfolio after 10y$21.3K$102.3K
Annual income after 10y$8.64$24,771.77
Total dividends collected$985.00$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GGDVF vs ABBV ($10,000, DRIP)

YearGGDVF PortfolioGGDVF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,027$327.28$11,550$430.00$523.00ABBV
2$12,022$223.29$13,472$627.96$1.4KABBV
3$13,015$150.61$15,906$926.08$2.9KABBV
4$14,027$100.87$19,071$1,382.55$5.0KABBV
5$15,076$67.26$23,302$2,095.81$8.2KABBV
6$16,176$44.73$29,150$3,237.93$13.0KABBV
7$17,338$29.69$37,536$5,121.41$20.2KABBV
8$18,571$19.69$50,079$8,338.38$31.5KABBV
9$19,884$13.05$69,753$14,065.80$49.9KABBV
10$21,285$8.64$102,337$24,771.77$81.1KABBV

GGDVF vs ABBV: Complete Analysis 2026

GGDVFStock

Guangdong Investment Limited, an investment holding company, engages in water resources, property investment and development, department store operation, energy project operation, road and bridge operation, and hotel businesses. Its Water Resources segment provides water distribution, sewage treatment, infrastructure and water pipeline installation services, as well as constructs water supply and sewage treatment infrastructure in Mainland China and Hong Kong. The company's Property Investment and Development segment invests in various properties in Hong Kong and Mainland China; and develops and sells properties in Mainland China. This segment also provides property management services for various commercial properties. Its Department Stores segment operates department stores in Mainland China. The company's Electric Power Generation segment operates coal-fired power plants that supply electricity and steam in the Guangdong province, Mainland China. The company's Hotel Operation and Management segment operate hotels and provides hotel management services to third parties in Hong Kong and Mainland China. As of December 31, 2021, this segment managed 27 hotels, including 3 in Hong Kong, 1 in Macau, and 23 in Mainland China. Its Road and Bridge segment invests in various road and bridge projects, which engages in the toll road operation and road management in Mainland China. The company's Others segment provides treasury services in Hong Kong and Mainland China, as well as corporate and other related services. The company was formerly known as Union Globe Development Limited and changed its name to Guangdong Investment Limited in January 1987. The company was incorporated in 1973 and is based in Central, Hong Kong. Guangdong Investment Limited is a subsidiary of GDH Limited.

Full GGDVF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GGDVF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GGDVF vs SCHDGGDVF vs JEPIGGDVF vs OGGDVF vs KOGGDVF vs MAINGGDVF vs JNJGGDVF vs MRKGGDVF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.